Skip to main content
Signal8

PALATIN TECHNOLOGIES INC (PTN)

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Palatin Technologies, Inc. logo

Palatin Technologies, Inc.

NASDAQ:PTNHealthcare
AH-1.12%$5.30
Close$5.36-12.49%
Mkt Cap$9.55M
EV-
Float1.69M
O/S1.78M
VOL53K sh
$ Vol$295K
RVOL1.28×
Inst Own55.5%
Net Cash/Sh-
Dilution
Palatin Technologies, Inc. logoNASDAQ:PTNAH$5.30-1.12%
Historical Data
DateOpenHighLowCloseVolume
Nov 17, 20266.066.155.255.3653,805
Nov 16, 20266.276.276.026.1318,867
Nov 13, 20266.386.395.816.2330,204
Nov 12, 20266.586.676.176.5713,487
Nov 11, 20267.177.176.736.8612,000
Nov 10, 20266.897.156.706.8925,217
Nov 9, 20266.697.336.237.23156,596
Nov 6, 20265.936.625.676.2733,994
Nov 5, 20266.026.044.765.7157,180
Nov 4, 20265.366.205.246.0251,426
Nov 3, 20265.055.685.055.2222,355
Nov 2, 20265.125.314.834.9930,715
Oct 30, 20264.935.114.895.0016,039
Oct 29, 20264.975.304.744.9312,214
Oct 28, 20264.655.174.515.1042,460
Oct 27, 20264.935.024.704.7733,292
Oct 26, 20265.105.424.584.8228,085
Oct 23, 20265.445.894.925.11126,577
Oct 22, 20265.755.785.505.5113,649
Oct 21, 20265.605.855.405.5520,481
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target
Not available
Ratings Distribution
BUY
3
HOLD
0
SELL
0
TOTAL3
Insider Trades
InsiderTypeShares
PRENDERGAST JOHN K A profile photoPRENDERGAST JOHN K AWithholding/Transfer2.9K
Morris Arlene profile photoMorris ArleneWithholding/Transfer2.4K
DUNTON ALAN W profile photoDUNTON ALAN WWithholding/Transfer2.2K
SPANA CARL profile photoSPANA CARLAutomatic Sell119
SPANA CARL profile photoSPANA CARLAutomatic Sell33
WILLS STEPHEN T profile photoWILLS STEPHEN TAutomatic Sell94
Shareholders
55.5%
Institutional
(31)
16.6%
Insiderⓘ
(5)
0.0%
5%+ Owners
(0)
27.9%
Unattributed (incl. retail)ⓘ
Institutional55.5%
Insider16.6%
Unattributed (incl. retail)27.9%
Sources: 13F, Form 4, 13D/13GO/S: 1.8M · as of 13 Nov 2026 · SEC filings
Insiders & Institutional Holders
About

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States.

The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder.

It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases.

In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis.

The company was incorporated in 1986 and is based in Cranbury, New Jersey.

Key Metrics
Market Cap$9.55M
Enterprise Value--
P/E Ratio-14.53
Est. Net Cash/Share--
Institutional Ownership55.46%

based on 1.78M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
CountryUSUS
IPO DateMay 29, 2026
Shares Outstanding1.78M
Authorized Shares
Float1.69M
52-Week Range
$4.51$31.00
$5.36(3rd percentile)
Volume
Average Daily Volume41.80K
53.80K today vs 41.80K avg(+29%)

30d Avg

41.80K

60d Avg

35.83K

90d Avg

72.66K

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...

Signal8's dilution snapshot of PTN as of Sep 30, 2026 records an at-the-market sales agreement dated Feb 11, 2025, 17 outstanding warrant series and a public offering closed Nov 12, 2025, from SEC filings. Palatin Technologies Inc. (NASDAQ: PTN) traded at $5.36 on Nov 17, 2026, down 12.49% from the previous close of $6.13. 52-week range: $4.51 to $31.00. The company is in the Healthcare sector (Biotechnology).